Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3911 ARTÍCULOS , VIENDO DEL 2476 AL 2490

Mouse Models of Huntington's Disease

Brooks SP, Dunnett SB.

Curr Top Behav Neurosci. 2015;22:101-33. doi: 10.1007/7854_2013_256.

The devil is in the details: confidentiality challenges in the age of genetics

Daly BJ, Rosko A, Zhang S, Lazarus HM.

HEC Forum. 2015 Mar;27(1):79-86. doi: 10.1007/s10730-014-9245-5.

Emerging biology of PDE10A

Wilson LS, Brandon NJ.

Curr Pharm Des. 2015;21(3):378-88. doi: 10.2174/1381612820666140826114744.

Phosphodiesterases as therapeutic targets for Huntington's disease

Fusco FR, Giampà C.

Curr Pharm Des. 2015;21(3):365-77. doi: 10.2174/1381612820666140826113957.

Neurobiology of Huntington's Disease

De Souza RA, Leavitt BR.

Curr Top Behav Neurosci. 2015;22:81-100. doi: 10.1007/7854_2014_353.

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

Süssmuth SD, Haider S, Landwehrmeyer GB, Farmer R, Frost C, Tripepi G, Andersen CA, Di Bacco M, Lamanna C, Diodato E, Massai L, Diamanti D, Mori E, Magnoni L, Dreyhaupt J, Schiefele K, Craufurd D, Saft C, Rudzinska M, Ryglewicz D, Orth M, Brzozy S, Baran A, Pollio G, Andre R, Tabrizi SJ, Darpo B, Westerberg G; PADDINGTON Consortium.

Br J Clin Pharmacol. 2015 Mar;79(3):465-76. doi: 10.1111/bcp.12512.

Safety, pharmacokinetics, pharmacogenomics and QT concentration-effect modelling of the SirT1 inhibitor selisistat in healthy volunteers

Westerberg G, Chiesa JA, Andersen CA, Diamanti D, Magnoni L, Pollio G, Darpo B, Zhou M.

Br J Clin Pharmacol. 2015 Mar;79(3):477-91. doi: 10.1111/bcp.12513.

The Neuropathology of Huntington's Disease

Waldvogel HJ, Kim EH, Tippett LJ, Vonsattel JP, Faull RL.

Curr Top Behav Neurosci. 2015;22:33-80. doi: 10.1007/7854_2014_354.

Invited review: decoding the pathophysiological mechanisms that underlie RNA dysregulation in neurodegenerative disorders: a review of the current state of the art

Walsh MJ, Cooper-Knock J, Dodd JE, Stopford MJ, Mihaylov SR, Kirby J, Shaw PJ, Hautbergue GM.

Neuropathol Appl Neurobiol. 2015 Feb;41(2):109-34. doi: 10.1111/nan.12187.

Implication of matrix metalloproteinases in regulating neuronal disorder

Mukherjee A, Swarnakar S.

Mol Biol Rep. 2015 Jan;42(1):1-11. doi: 10.1007/s11033-014-3752-y.

Linking genes to neurological clinical practice: the genomic basis for neurorehabilitation

Goldberg A, Curtis CL, Kleim JA.

J Neurol Phys Ther. 2015 Jan;39(1):52-61. doi: 10.1097/NPT.0000000000000066.

Huntington disease: pathogenesis and treatment

Dayalu P, Albin RL.

Neurol Clin. 2015 Feb;33(1):101-14. doi: 10.1016/j.ncl.2014.09.003.

Characterization of intracellular aggresomes by fluorescent microscopy

Fu L, Sztul E.

Methods Mol Biol. 2015;1258:307-17. doi: 10.1007/978-1-4939-2205-5_17.

Application of Proteomic Tools in Modern Nanotechnological Approaches Towards Effective Management of Neurodegenerative Disorders

Ali A, Sheikh IA, Mirza Z, Gan SH, Kamal MA, Abuzenadah AM, Damanhouri GA, Ashraf GM.

Curr Drug Metab. 2015;16(5):376-88. doi: 10.2174/1389200216666141208153303.

Benzothiazoles - scaffold of interest for CNS targeted drugs

Hroch L, Aitken L, Benek O, Dolezal M, Kuca K, Gunn-Moore F, Musilek K.

Curr Med Chem. 2015;22(6):730-47. doi: 10.2174/0929867322666141212120631.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias